Abstract
CDK 4/6 inhibitors (CDK 4/6i) are indicated for use in combination with aromatase inhibitors or fulvestrant for HR+/HER2- metastatic breast cancer (mBC). The class was first available for use in 2017 with the approval and reimbursement of palbociclib, and later ribociclib and abemaciclib. Equal care across the 21 regions in Sweden is a key element on the Swedish health care agenda. The objective of this study was to investigate the utilization of CDK 4/6i in the 21 Swedish regions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
